Strategic Expansion into Animal Health Citi Pharma Limited has officially launched its wholly owned subsidiary, Citi Veterinary Limited, marking a bold expansion into Pakistan’s growing veterinary pharmaceutical market. The company announced the start of trading operations and the rollout of 32 veterinary products, including vaccines, with letters of credit already established for eight key items to ensure uninterrupted supply.

Revenue Targets and Market Ambitions For the fiscal year 2025–26, Citi Veterinary projects a turnover of Rs1.5 billion with an initial gross margin of 13%. The company aims to scale operations aggressively, targeting Rs10 billion in turnover within three years, signaling strong confidence in the demand for animal health solutions across Pakistan’s livestock and poultry sectors.

Supply Chain Strength and Chinese Partnerships To support its product rollout, Citi Veterinary has partnered with Chinese supply chain firms to guarantee consistent availability of veterinary medicines in Pakistan. These partnerships are expected to stabilize inventory and reduce procurement delays, especially for high-demand vaccines and treatments.

Production Roadmap and Regulatory Milestones Citi Veterinary has submitted its plant layout to the Drug Regulatory Authority of Pakistan (DRAP), with inspection scheduled for December 2025. The company plans to begin trial production by late fiscal 2025–26, followed by full commercial production in 2026–27.

Pakistan’s First Veterinary API Plant In a landmark move, Citi Veterinary intends to establish Pakistan’s first dedicated veterinary active pharmaceutical ingredient (API) plant during fiscal 2026–27. This facility will enable in-house production of core ingredients, significantly improving supply chain control and boosting gross profit margins to an estimated 25%.

Conclusion: A New Chapter in Veterinary Healthcare Citi Pharma’s expansion into veterinary medicine reflects a strategic response to rising demand for quality animal healthcare in Pakistan. With ambitious revenue goals, regulatory alignment, and infrastructure investment, Citi Veterinary is poised to become a key player in the country’s pharmaceutical landscape—bridging gaps in livestock treatment and veterinary innovation.